分子机制和家族性肌缩侧面硬化症的反感性寡核酸疗法
Hussain Al Dera1,2, Bdour AlQahtani3
1Department of Basic Medical Sciences, College of Medicine at King Saud, Abdulaziz University for Health Sciences (KSAU-HS), Riyadh, Saudi Arabia.
Molecular therapy. Nucleic acids
|August 23, 2024
概括
家庭性肌缩侧面硬化 (fALS) 遗传学涉及SOD1和C9orf72.2等基因的突变. 反感性寡核酸 (ASO) 为这种神经退行性疾病提供了一个有前途的治疗策略.
科学领域:
- 神经科学是一个神经科学.
- 遗传学 遗传学 是一个
- 分子生物学分子生物学
背景情况:
- 肌缩侧面硬化症 (ALS) 是一种进展性神经退行性疾病,具有诊断和治疗方面的挑战.
- 家族性ALS (fALS) 占病例的10%左右,通常以自体主导模式遗传.
研究的目的:
- 为了审查fALS.的分子遗传学.
- 突出导致fALS病变的关键突变.
- 探索反感性寡核酸 (ASOs) 作为fALS.的治疗策略.
主要方法:
- 在fALS.分子遗传学的文献综述.
- 对关键基因突变 (例如,SOD1,FUS,C9orf72) 的分析.
- 对反感性寡核酸 (ASO) 机制和治疗潜力的评估.
主要成果:
- 鉴定了关键的基因突变 (SOD1,FUS,C9orf72),这些突变与fALS的病原发生有关.
- 详细介绍了这些遗传异常背后的分子机制.
- 突出了ASO在针对这些遗传缺陷方面的潜力.
结论:
- 了解fALS分子遗传学对于开发向疗法至关重要.
- 通过解决特定的遗传突变,ASOs代表了对fALS的有希望的治疗途径.
- 本综述提供了对神经退行性疾病 (如fALS) 新型治疗策略的见解.
相关概念视频
siRNA - Small Interfering RNAs
16.7K
Small interfering RNAs, or siRNAs, are short regulatory RNA molecules that can silence genes post-transcriptionally, as well as the transcriptional level in some cases. siRNAs are important for protecting cells against viral infections and silencing transposable genetic elements.
In the cytoplasm, siRNA is processed from a double-stranded RNA, which comes from either endogenous DNA transcription or exogenous sources like a virus. This double-stranded RNA is then cleaved by the...
In the cytoplasm, siRNA is processed from a double-stranded RNA, which comes from either endogenous DNA transcription or exogenous sources like a virus. This double-stranded RNA is then cleaved by the...
16.7K
Alzheimer's Disease: Treatment
170
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
170
Amyloid Fibrils
9.3K
Amyloid fibrils are aggregates of misfolded proteins. Under most circumstances, misfolded proteins are either refolded by chaperone proteins or degraded by the proteasome. However, in the case of a mutation or a disease, these proteins can accumulate to form large clusters and often further assemble to form elongated fibers, called fibrils.
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...
9.3K
Parkinson's Disease: Overview
500
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
500
Experimental RNAi
6.1K
RNA interference (RNAi) is a cellular mechanism that inhibits gene expression by suppressing its transcription or activating the RNA degradation process. The mechanism was discovered by Andrew Fire and Craig Mello in 1998 in plants. Today, it is observed in almost all eukaryotes, including protozoa, flies, nematodes, insects, parasites, and mammals. This precise cellular mechanism of gene silencing has been developed into a technique that provides an efficient way to identify and determine the...
6.1K
RNA Interference
26.0K
RNA interference (RNAi) is a process in which a small non-coding RNA molecule blocks the post-transcriptional expression of a gene by binding to its messenger RNA (mRNA) and preventing the protein from being translated.
This process occurs naturally in cells, often through the activity of genomically-encoded microRNAs. Researchers can take advantage of this mechanism by introducing synthetic RNAs to deactivate specific genes for research or therapeutic purposes. For example, RNAi could be used...
This process occurs naturally in cells, often through the activity of genomically-encoded microRNAs. Researchers can take advantage of this mechanism by introducing synthetic RNAs to deactivate specific genes for research or therapeutic purposes. For example, RNAi could be used...
26.0K


